Current Medical Research and Opinion 2005; 21(12): 2063-71, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Roze S, Diabetic Medicine 2005; 22(9): 1239-45, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK.
Ray JA, Current Medical Research and Opinion 2005; 21(10): 1617-29, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Minshall ME, Roze S, Palmer AJ, Clinical Therapeutics 2005; 27(6): 940-50, Foos V, Ray J, Graham C. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States.
Palmer AJ, Tucker DM, Nephrology Dialysis Transplantation 2005; 20(6): 1103-9, Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
Palmer AJ, Current Medical Research and Opinion 2005; 21(1): 19-26, Roze S, Lammert M, Spiesser J, Gabriel S. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries.